PGIMER’s Clinical Trial of Sepsivac For Covid-19 Treatment
The Post Graduate Institute of Medical Education and Research in Chandigarh announced that they have started the clinical trial of Sepsivac on asymptomatic coronavirus patients.
Amid the rising number of Covid-19 patients in India, on Wednesday, the clinical trial of Sepsivac on asymptomatic coronavirus patients has started by the Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh. The coordinator of the trial program for using Sepsivac in Covid-19 treatment, and the CSIR-IIM Director, Dr. Ram Vishwakarma said that to position the immunomodulator Sepsivac as a drug, PGIMER Chandigarh has begun the clinical trials.
He added that they are also doing another trial on asymptomatic Covid-19 patients, where the drug would be given to the patients as a vaccine for the infection.
At the Post Graduate Institute of Medical Education and Research in Chandigarh, the coordinator of the trial program, Dr. Ram Vishwakarma said that to ensure that coronavirus patients do not redevelop the infection, the immunomodulator Sepsivac would be given as a vaccine.
He said that the third trial would be on patients who have been cured and released for quarantine as the coronavirus is capable of lingering in a patient for one month. To prevent them from redeveloping the infection, this would be given as vaccines.
He added that if the trials of Sepsivac are successful, a large number of lives could be saved. It would take a minimum of 3 months to be available for Covid-19 treatment if it works.
As of 30 April Afternoon, the number of confirmed coronavirus cases in India is at 33,338 with 23,748 active cases. There have been more than a thousand deaths caused by the infection with the death toll at 1082 and around 8058 patients have recovered from the Covid-19 infection. The highest number of active cases is in the state of Maharashtra.